Background/objective: Progression of joint damage is linked to disease activity. This link is dissociated upon treatment with tumour necrosis factor (TNF)- or IL-6-inhibitors plus methotrexate (MTX). It is hitherto unknown if this may also be true for therapies targeting B-cells. We thus evaluated if rituximab (RTX) therapy inhibits joint damage irrespective of its effects on disease activity.

Methods: We used a random 90% sample of data from two arms of the IMAGE trial comprising patients with active early rheumatoid arthritis (RA) receiving MTX (n=188) or MTX+RTX 1000 mg (n=204). Patients were divided into low, moderate and high disease activity at one year of treatment by simplified disease activity index (low disease activity (LDA), moderate disease activity (MDA), high disease activity (HDA)), or by swollen joint count (SJC) or C reactive protein (CRP) tertiles. Progression of damage by the Genant modified total Sharp score (TGSS) was compared between therapies (Kruskal-Wallis, Wilcoxon tests) for each of these subgroups.

Results: In patients treated with MTX, 1-year progression of TGSS In LDA, MDA and HDA was 0.40±0.88, 1.04±1.73, and 1.31±3.02, respectively. In contrast, on RTX+MTX, TGSS progression was 0.38±1.07, 0.39±1.28, and -0.05±0.44, respectively (for MDA and HDA the progression of TGSS was significantly lower in the combined group than in the MTX group: p=0.003 and p=0.05, respectively). Additional analyses (tertiles of SJC, CRP, and matching for disease activity) confirmed the primary analysis.

Conclusions: In early RA, progression of joint damage increases with increasing disease activity on MTX. RTX plus MTX retards damage independently of its effects on disease activity, since even in HDA destruction is halted, contrasting MTX monotherapy. This indicates that beyond cytokine blockade (TNF- and IL-6 inhibitors), also cell-directed therapy (anti-CD20 antibody) conveys profound anti-destructive effects and dissociates the link between disease activity and joint damage.

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-201970DOI Listing

Publication Analysis

Top Keywords

disease activity
44
joint damage
20
disease
12
activity
11
link disease
8
activity joint
8
rheumatoid arthritis
8
progression joint
8
effects disease
8
high disease
8

Similar Publications

Daily Path Areas and Location Use During and After Cardiac Rehabilitation.

J Cardiopulm Rehabil Prev

January 2025

Author Affiliations: Faculty of Health, Dalhousie University, Halifax, Nova Scotia, Canada (Ms Langley); Bluewater Health, Sarnia, Ontario, Canada and School of Kinesiology (Exercise and Health Psychology Lab), Western University, London, Ontario, Canada (Dr Campbell); Physical Activity and Chronic Disease Prevention Unit, University of British Columbia, Vancouver, British Columbia, Canada(Dr Warburton); School of Exercise Science, Physical and Health Education, Faculty of Health, University of Victoria, Victoria, British Columbia, Canada (Dr Rhodes); Department of Kinesiology & Physical Education, McGill University, Montreal, Quebec, Canada (Dr Sweet); Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Giacomantonio); School of Health and Human Performance and the Healthy Populations Institute, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Rainham); Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, Manitoba, Canada (Dr Strachan); Department of Applied Human Sciences, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada (Dr Saunders); and Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Blanchard).

Purpose: Little research has focused on the potential impact that the environment plays in shaping cardiac rehabilitation (CR) patient sedentary time (ST) and physical activity (PA). To address this, the current study generated daily path areas (DPAs) based on the locations they visited during and after they completed CR.

Methods: Patients in CR (n = 66) completed a survey and wore an accelerometer and Global Positioning System receiver for 7 days early (first month), late (last 2 weeks of program), and 3 months after completing CR.

View Article and Find Full Text PDF

Research progress of Sinomenium in the treatment of rheumatoid arthritis and suggestions for future research.

Allergol Immunopathol (Madr)

January 2025

Bone and Joint Research Team of Degeneration and Injury, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.

Rheumatoid arthritis (RA) is a chronic autoimmune joint disease. Its main pathological manifestations are joint cartilage, bone tissue injury, synovial hyperplasia, and chronic inflammation. At present, the pathogenesis of the disease has not been fully defined, and delaying the disease to improve joint function is the existing treatment.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation, airway obstruction, and lung damage, often triggered by cigarette smoke. Dysregulated autophagy and inflammation are key contributors to its progression. Although double-stranded RNA-binding protein Staufen homolog 1 (STAU1), a multifunctional protein primarily involved in mRNA transport and localization, is identified as a potential biomarker, its role in COPD pathogenesis remains unclear.

View Article and Find Full Text PDF

Acanthoside B attenuates NLRP3-mediated pyroptosis and ulcerative colitis through inhibition of tAGE/RAGE pathway.

Allergol Immunopathol (Madr)

January 2025

Department of Neurofunction, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China;

Acanthoside B (Aca.B), a principal bioactive compound extracted from , exhibits superior anti-inflammatory capacity. Ulcerative colitis is a nonspecific inflammatory bowel disease with unknown etiology.

View Article and Find Full Text PDF

Background: Atopic dermatitis (AD) is a disease of multifactorial etiology that affects the quality of life of those afflicted.

Objective: The degree of control of patients with AD over 12 years of age was determined with the Atopic Dermatitis Control Instrument (ADCT).

Material And Methods: This observational, cross-sectional, descriptive study included patients with AD who were evaluated with a self-administered instrument, the ADCT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!